Related Experiment Video
Updated: May 23, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Vasodilating versus first-generation β-blockers for cardiovascular protection.
Hassan Fares1, Carl J Lavie, Hector O Ventura
1Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, LA, USA.
Postgraduate Medicine
|March 23, 2012
Summary
Newer beta-blockers like carvedilol offer improved metabolic effects and vasodilation for hypertension management, unlike older agents. These advancements benefit patients with comorbid conditions and cardiovascular issues.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Metabolic Health
Background:
- Traditional beta-blockers (e.g., atenolol, metoprolol) face scrutiny for hypertension treatment due to adverse metabolic effects.
- Concerns exist regarding the efficacy of traditional beta-blockers in patients with comorbid conditions.
Purpose of the Study:
- To evaluate the evolving role of newer generation beta-blockers in hypertension management.
- To highlight the distinct mechanisms and benefits of novel beta-blockers compared to traditional ones.
Main Methods:
- Comparative analysis of traditional (atenolol, metoprolol) and newer generation (carvedilol, nebivolol) beta-blockers.
- Review of studies examining cardiovascular and metabolic effects.
Main Results:
- Newer beta-blockers (carvedilol, nebivolol) demonstrate favorable metabolic profiles.
- These agents possess vasodilatory properties via A1 adrenoreceptor inhibition and nitric oxide influence, unlike traditional beta-blockers.
- Beneficial cardiovascular effects are maintained in post-myocardial infarction and heart failure populations.
Conclusions:
- Novel beta-blockers represent a significant advancement in hypertension therapy.
- Carvedilol and nebivolol offer improved outcomes and tolerability, particularly in patients with comorbidities.
- The vasodilatory and metabolic benefits position newer beta-blockers as valuable therapeutic options.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...